Squalane Toxicity
Identifiers
Functions
What are the material safety considerations for SQUALANE?
SQUALANE is considered safe for use in cosmetics under current practices, based on a Cosmetic Ingredient Review finding in rats. No GHS hazard classifications or exposure limits are available in the supplied evidence, indicating no standardized hazard statements or occupational thresholds are documented. This supports its use as a low-risk emollient, but formulators should still rely on general good manufacturing practices. The absence of GHS data does not confirm zero hazard; it reflects a lack of submitted classifications. For regulatory submissions, this safety profile is favorable, but confirmatory data may be needed for specific markets.
How should hazard classifications and toxicology findings for SQUALANE be interpreted together?
The available toxicology finding—a CIR safety assessment in rats—should be interpreted as a positive safety signal for current cosmetic use, but it is not a substitute for GHS hazard classifications. The absence of GHS data means no standardized hazard statements (e.g., acute toxicity, skin irritation) are available to compare against the CIR conclusion. Together, the evidence suggests a favorable safety profile for topical application, but the lack of GHS classifications limits the ability to assess occupational or accidental exposure scenarios. For formulation decisions, the CIR finding supports use, while the missing GHS data should be noted as a gap for comprehensive risk assessment.
Which exposure routes, dose contexts, or effects are material for SQUALANE?
The primary exposure route for SQUALANE in cosmetics is dermal, given its functions as a skin conditioning agent, emollient, and hair conditioning ingredient. The CIR safety finding in rats supports dermal safety at current use concentrations, but no specific dose or concentration data are provided. Inhalation or oral exposure are not addressed in the evidence, so occupational or accidental ingestion risks remain uncharacterized. For product development, this means dermal exposure is the main consideration, and the lack of quantitative exposure limits (e.g., PEL, TLV) should be acknowledged. Formulators should ensure use levels align with established cosmetic practices.
Which handling and risk-management measures are relevant for SQUALANE?
Given the absence of GHS hazard classifications and exposure limits, standard handling precautions for low-risk cosmetic ingredients are appropriate. The CIR finding of safety in current practices suggests no special engineering controls are required for dermal exposure. However, since no occupational exposure limits are available, general hygiene measures—such as avoiding prolonged skin contact and using gloves if handling large quantities—are prudent. The lack of specific risk-management data means formulators should follow existing safety data sheets and regulatory guidance for cosmetic ingredients. No additional controls are indicated by the evidence, but the gap in exposure limits should be considered for industrial handling scenarios.
Which safety evidence gaps should be resolved before making decisions about SQUALANE?
Before making final decisions, the key evidence gap is the absence of GHS hazard classifications and exposure limits for SQUALANE. While the CIR finding supports safety in current cosmetic use, it does not provide quantitative thresholds for occupational exposure or acute toxicity. Additionally, no data on inhalation, oral toxicity, or specific dose-response relationships are available. These gaps are material for regulatory submissions and for assessing non-dermal exposure scenarios. Resolving them would require obtaining GHS classifications and exposure limit data from authoritative sources. Until then, the safety profile is based on a single CIR assessment, which is sufficient for cosmetic use but not for broader risk assessments.